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The Middle East respiratory syndrome coronavirus (MERS-CoV) was discovered in 2012 on the Arabian Peninsula as the causative agent of acute respiratory distress (and renal failure), with an unusually high fatality rate of \~35% (ref. ^[@CR1]^). The vast majority of the 2,482 confirmed cases were reported in the Middle East, although the virus was introduced into 27 countries. A total of 203 new MERS-CoV cases were reported in 2019 and there is currently no vaccine or cure for MERS or any coronavirus-induced diseases in humans. Zoonotic MERS-CoV transmission from dromedary camels (the host reservoir for this virus) along with human-to-human transmission are the two known modes of infection^[@CR2],[@CR3]^. Future emergence of (zoonotic) coronaviruses is likely to occur, given the large reservoir in bats and birds, underscoring the importance of studying these pathogens^[@CR4]--[@CR7]^.

MERS-CoV is an enveloped Nidovirus decorated with homotrimers of the spike (S) glycoprotein that mediates entry into host cells. S is the major antigen present at the viral surface and is the target of neutralizing antibodies during infection as well as the focus of vaccine design. Recent cryo-EM structures of MERS-CoV and related coronavirus S ectodomain trimers provided snapshots of this key protein in prefusion^[@CR8]--[@CR15]^ and postfusion^[@CR16]^ conformations, receptor-bound states^[@CR17]--[@CR19]^ and in complex with neutralizing antibodies^[@CR20],[@CR21]^. MERS-CoV S is composed of an N-terminal S~1~ subunit, which is folded as four domains (A--D) and mediates attachment to dipeptidyl-peptidase 4 (DPP4, the host receptor)^[@CR22]^, and a C-terminal S~2~ subunit that merges the viral and cellular membranes to initiate infection. MERS-CoV S is cleaved at the junction between the S~1~ and S~2~ subunits either during viral biogenesis or upon encounter of target cells^[@CR23]--[@CR26]^. A second cleavage site, designated S~2~′, is found upstream of the fusion peptide in the S~2~ subunit and is processed at the onset of membrane fusion. Both cleavage sites participate in enhancing viral entry and modulating host range and cell tropism^[@CR23],[@CR24],[@CR27]^.

Sialic acids (derivatives of neuraminic acid) are ubiquitous carbohydrates found as terminal residues on glycoproteins and glycolipids decorating the surface of eukaryotic cells. Neuraminic acid modifications, along with the formation of specific glycosidic linkages, result in a wide chemical variety of sialoglycoconjugates across cell types, tissues and animal species^[@CR28]^. As a result, differential sialoside recognition can profoundly impact the zoonotic transmission, tropism and virulence of many viruses. For example, a few amino acid substitutions in influenza virus hemagglutinins account for the preference switch from avian enteric tract to human respiratory tract sialylated receptors^[@CR29]--[@CR31]^.

MERS-CoV primarily infects human lung epithelial cells upon interacting with DPP4 (ref. ^[@CR22]^). Crystal structures of the MERS-CoV S domain B in complex with the DPP4 ectodomain^[@CR32],[@CR33]^, along with cryo-EM structures of the MERS-CoV S ectodomain trimer^[@CR15],[@CR20],[@CR21]^, have furthered our understanding of the mechanism of DPP4 engagement. In addition to attachment to DPP4, we recently showed that MERS-CoV infection of human airway epithelial cells involves low-affinity interactions with sialosides, using the S glycoprotein domain A, as depletion of sialic acid from the cell surface dampened viral entry^[@CR34]^. A binding preference was found for α2,3-linked over α2,6-linked sialosides, and these interactions were hindered by 9-O-acetylation or 5-N-glycolylation of the terminal neuraminic acid^[@CR34]^. Furthermore, we found that MERS-CoV S sialylated receptors are abundant in the camel nasal respiratory epithelium and the human lung alveoli, which coincides with DPP4 expression and the sites of MERS-CoV replication in these mammals^[@CR34],[@CR35]^. As sialoside modifications, linkages and distribution vary among and within host species, the selectivity of MERS-CoV S for certain sialoside glycotopes may provide a determinant of host and tissue tropism of this zoonotic pathogen. These findings provided a plausible rationale for explaining that equine DPP4 could support MERS-CoV infection of cultured cells, although horses were found to be resistant to experimental MERS-CoV infection (despite the presence of DPP4 in their respiratory tract)^[@CR36]--[@CR38]^. Although sialoside attachment appears to be a key step modulating MERS-CoV infection, the location of the sialoside-binding site, the interactions involved in ligand recognition and the molecular basis for receptor specificity remain unknown. This information is crucial for understanding viral tropism and infectivity, assessing the zoonotic potential of MERS-CoV and related coronaviruses, and providing a blueprint for the design of coronavirus inhibitors.

To understand the structural basis of MERS-CoV attachment to and specificity for host sialosides, we determined cryo-EM structures of the S glycoprotein ectodomain trimer in complex with 5-*N*-acetyl neuraminic acid (Neu5Ac), 5-*N*-glycolyl neuraminic acid (Neu5Gc), sialyl-Lewis^X^ (sLeX), α2,3-sialyl-*N*-acetyl-lactosamine (2,3-SLN) and α2,6-sialyl-*N*-acetyl-lactosamine (2,6-SLN) at 2.7, 3.0, 2.7, 2.7 and 2.9 Å resolution, respectively. We demonstrate that the receptor binds in a groove located at the surface of domain A that is distinct from the 9-*O*-acetyl sialoside-engagement site identified for HCoV-OC43 and related β-1 coronavirus S glycoproteins^[@CR19],[@CR39]^. We further show that the residues involved in Neu5Ac recognition are conserved across MERS-CoV isolates and essential for MERS-CoV S-mediated hemagglutination of human erythrocytes and entry into human airway epithelial cells. Our data rationalize MERS-CoV S attachment to neuraminic acids that are not 9-O-acetylated or 5-N-glycolylated and suggest an explanation for the selectivity for α2,3-linked over α2,6-linked sialosides. This study provides a structural framework for understanding MERS-CoV S sialoglycan receptor engagement and specificity, illuminates host range and cell tropism, and identifies a site of vulnerability accessible to neutralizing antibodies and small-molecule inhibitors.

Results {#Sec2}
=======

A sialoside-binding site in the MERS-CoV S glycoprotein {#Sec3}
-------------------------------------------------------

To identify the MERS-CoV S sialoside-recognition site, we determined a cryo-EM structure of the MERS-CoV S 2P stabilized ectodomain trimer^[@CR21]^ incubated with 100 mM Neu5Ac at 2.7 Å resolution (Fig. [1a](#Fig1){ref-type="fig"}, Extended Data Figs. [1a](#Fig5){ref-type="fig"} and [2a--g](#Fig6){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}). The presence of the sialoside stabilized a large fraction of MERS-CoV S trimers in the closed state, with all three DPP4-binding B domains adopting a down conformation, obeying three-fold symmetry. We did not detect major conformational changes compared to closed protomers of the LCA60 Fab-bound MERS-CoV S structure^[@CR20]^ (Cα r.m.s. deviation (r.m.s.d.) of 1.35 Å for 1,145 aligned residues). The resolution estimate of our map is supported by the detection of ordered water molecules^[@CR40]^ interacting with the S glycoprotein (Extended Data Fig. [1f,g](#Fig5){ref-type="fig"}) and by the observation of folic acid bound to S, as previously identified using X-ray crystallography and mass spectrometry of isolated domain A^[@CR21]^. The density is equally well resolved for the ligand and the surrounding S amino acid residues, allowing unambiguous identification of the binding site and docking of Neu5Ac in the map (Extended Data Fig. [1d](#Fig5){ref-type="fig"}). The ligand interacts with a groove located at the periphery of domain A that is distinct from the HCoV-OC43 S 9-*O*-acetyl sialoside-binding site^[@CR19]^ (Figs. [1a--e](#Fig1){ref-type="fig"} and [2a--c](#Fig2){ref-type="fig"}). The absence of N-linked glycans in the immediate vicinity of the binding groove probably facilitates unobstructed engagement of sialoglycoconjugates at the surface of target cells (Fig. [2a](#Fig2){ref-type="fig"}). The ligand-binding site is located \~50 and \~75 Å away from the DPP4-binding site of a neighboring B domain in the closed or open state, respectively (Fig. [1b](#Fig1){ref-type="fig"}).Fig. 1Cryo-EM identification of a sialoside-binding site in the MERS-CoV S glycoprotein.**a**, Molecular surface representation of the MERS-CoV S ectodomain trimer, with each protomer in a different color. The Neu5Ac ligands are rendered as spheres. **b**, Spatial relationships between the attachment (sialoside) and entry (DDP4) receptor-binding sites are illustrated using a composite model obtained from the cryo-EM structure shown in **a**, the cryo-EM structure of MERS-CoV S bound to the LCA60 neutralizing antibody Fab fragment (PDB [6NB3](https://www.rcsb.org/structure/6NB3))^[@CR20]^ and a crystal structure of the MERS-CoV S domain B bound to DPP4 (PDB [4KR0](https://www.rcsb.org/structure/4KR0))^[@CR32]^. The sialoside-binding site is located \~50 and \~75 Å away from the DPP4-binding site of a neighboring B domain in the closed or open state, respectively. **c**, Surface representation of the ligand-binding site colored by electrostatic potential from −12 (red) to +10 (blue) *k*~B~*T*/*e*~c~. Neu5Ac is shown in stick representation. **d**,**e**, Two orthogonal views of the sialoside-binding site rendered as a ribbon diagram with the side chains of key surrounding residues shown as sticks. Neu5Ac is rendered as sticks and the corresponding region of cryo-EM density is shown as a blue mesh contoured at 5.5*σ*. Dashed lines show selected electrostatic interactions formed between MERS-CoV S amino acid residues and the ligand. In all panels, nitrogen and oxygen atoms are colored blue and red, respectively, while carbon atoms are colored gray (Neu5Ac) or pink (MERS-CoV S). Glycans in MERS-CoV S have been omitted for clarity.Table 1Cryo-EM data collection and refinement statisticsMERS-CoV S + Neu5Ac ([EMD-20542](https://www.ebi.ac.uk/pdbe/entry/emdb/EMD-20542), PDB [6Q04](https://www.rcsb.org/structure/6Q04))MERS-CoV S + Neu5Gc ([EMD-20829](https://www.ebi.ac.uk/pdbe/entry/emdb/EMD-20829))MERS-CoV S + sLeX ([EMD-20543](https://www.ebi.ac.uk/pdbe/entry/emdb/EMD-20543), PDB [6Q05](https://www.rcsb.org/structure/6Q05))MERS-CoV S + 2,3-SLN ([EMD-20544](https://www.ebi.ac.uk/pdbe/entry/emdb/EMD-20544), PDB [6Q06](https://www.rcsb.org/structure/6Q06))MERS-CoV S + 2,6-SLN ([EMD-20545](https://www.ebi.ac.uk/pdbe/entry/emdb/EMD-20545), PDB [6Q07](https://www.rcsb.org/structure/6Q07))**Data collection and processing**Magnification130,000130,000130,000130,000130,000Voltage (kV)300300300300300Electron exposure (e^--^ Å^--2^)7070707070Defocus range (μm)0.5--3.00.5--2.00.4--2.50.5--2.20.5--3.0Pixel size (Å)0.5250.5250.5250.5250.525Symmetry imposed*C*3*C*3*C*3*C*3*C*3Initial particle images (no.)380,000592,165790,614347,750251,814Final particle images (no.)42,07523,28157,35949,80423,659Map resolution (Å)2.73.02.72.72.9FSC threshold0.1430.1430.1430.1430.143**Refinement**Model resolution (Å)2.82.82.83.1FSC threshold0.50.50.50.5Map sharpening *B* factor (Å^2^)−61−57−62−59−54Model compositionProtein residues3,4773,4773,4773,477Ligands6666Water molecules *B* factors (Å^2^)23419521660Protein12.111.112.016.2Ligands1916.718.924.6Water molecules9.68.99.114R.m.s. deviationsBond lengths (Å)0.0260.0260.0260.026Bond angles (°)2.02.02.02.0**Validation**MolProbity score0.981.041.010.99Clashscore2.12.542.282.19Poor rotamers (%)0.20.20.20.2Ramachandran plotFavored (%)98.3598.2698.3598.35Allowed (%)99.9199.9199.9199.91Disallowed (%)0.090.090.090.09EMRinger score4.434.274.54.66Fig. 2MERS-CoV S and HCoV-OC43 S glycoproteins interact with sialosides, using distinct binding grooves.**a**,**b**, Molecular surface representation of the MERS-CoV S (**a**) and HCoV-OC43 S (**b**) A domains bound to Neu5Ac and 5-*N*-acetyl,9-*O*-acetyl neuraminic acid α-methyl glycoside (9-*O*-Ac-Neu5Ac, PDB [6NZK](https://www.rcsb.org/structure/6NZK)^[@CR19]^), respectively, and oriented identically. The sialosides are rendered as sticks with carbon, nitrogen and oxygen atoms colored gray, blue and red, respectively. N-linked glycans observed in the cryo-EM reconstructions are rendered as dark blue spheres. **c**, Ribbon diagrams of superimposed MERS-CoV S (pink) and HCoV-OC43 S (gold) A domains with bound sialosides. The sialosides are rendered as sticks with carbon, nitrogen and oxygen atoms colored pink (MERS-CoV S) or gold (HCoV-OC43 S), blue and red, respectively.

The ligand C1 carboxylate electrostatically interacts with the Ser133 side chain hydroxyl, and the 5-nitrogen atom is hydrogen-bonded to the Ile132 backbone carbonyl (Fig. [1c--e](#Fig1){ref-type="fig"}). The Neu5Ac hydroxyl group at position 8 is hydrogen-bonded to the Arg307 side chain guanidium whereas the hydroxyl group at position 9 interacts with the Arg307 guanidium as well as the Ala92 backbone amide and carbonyl oxygen via hydrogen bonding (Fig. [1c--e](#Fig1){ref-type="fig"}). The ligand *N*-acetyl methyl inserts into a hydrophobic depression defined by residues Phe39, Phe101, Ile131 and Ile132 whereas the *N*-acetyl carbonyl oxygen is hydrogen-bonded to the Gln36 side chain amide (Fig. [1c--e](#Fig1){ref-type="fig"}). The sialoside buries 280 Å^2^ of it surface upon MERS-CoV S engagement, corresponding to 61% of the ligand total accessible surface area, with most interactions occurring on the same side of the ligand. Bioinformatics analysis of MERS-CoV isolates shows that the residues contacting the sialoside or participating in the formation of the binding groove are conserved. Specifically, Gln36, Phe39, Phe101, Ile132 and R307 are strictly conserved in the 284 MERS-CoV isolates sequenced so far. The H91Y substitution is observed in four MERS-CoV isolates (human/Korea/Seoul/168--1--2015 GB, ALB08311; human/Korea/Seoul/168-2-2015 GB, ALB08322; human/KOR/Seoul/014-2015 GB, ANC28634.1; human/Riyadh_1337/KSA/2014 GB, AMW90853.1), the S133N or S133R substitutions are present in two isolates (human/England/4/2013 GB, AJD81440.1 and Hu/Quaseem-KSA-18012872/2018 GB, QBF80608.1, respectively) and the Q304K substitution is observed in 1 isolate (camel/UAE/D1164.11/2014 GB, AJG44080.1).

The architecture of the binding groove suggests 9-O-acetylation of the neuraminic acid could not be sterically accommodated (Extended Data Fig. [3a](#Fig7){ref-type="fig"}), in agreement with the previously reported distinct specificity of MERS-CoV S compared to HCoV-OC43 S^[@CR34]^. To assess if 5-N-glycolylation of the neuraminic acid could be tolerated, we determined a cryo-EM structure of MERS-CoV S 2P incubated with 100 mM Neu5Gc at 3.0 Å resolution (Extended Data Figs. [1b](#Fig5){ref-type="fig"}, [3b--f](#Fig7){ref-type="fig"} and [4a--d](#Fig8){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}). Comparison of this map with the MERS-CoV S/Neu5Ac map shows that the Neu5Gc density is weaker than that of the Neu5Ac and the glycolyl hydroxyl group could not be resolved, even after extensive focused 3D classification of the data (Extended Data Fig. [3b--f](#Fig7){ref-type="fig"}). This observation is in line with the reported MERS-CoV S binding preference to Neu5Ac compared to Neu5Gc based on the lack of hemagglutination of (Neu5Gc-rich) horse erythrocytes and absence of binding to Neu5Gc-containing sialosides on a glycan array^[@CR34]^. The structure suggests the MERS-CoV S hydrophobic pocket defined by Phe39, Phe101, Ile131 and Ile132 could sterically and/or chemically disfavor accommodation of the 5-*N*-glycolyl hydroxyl group in the conformation observed in virtually all Neu5Gc-containing protein complex structures (Extended Data Fig. [3b--f](#Fig7){ref-type="fig"}). The high concentrations of sialosides used for the cryo-EM experiments, however, allowed us to visualize Neu5Gc bound to MERS-CoV S, much in the same way that crystal structures of influenza virus hemagglutinins in complex with mismatched receptor analogs or of rhesus rotavirus VP8\* bound to Neu5Gc were obtained in spite of very weak or lack of detectable interactions in solution^[@CR29],[@CR30],[@CR41]^. Because the equine respiratory tract is abundantly decorated with Neu5Gc-containing oligosaccharides^[@CR42]^, these data collectively suggest a plausible explanation for the resistance of horses to experimental MERS-CoV infection, despite the fact MERS-CoV S can use equine DPP4 for promoting entry into target cells in vitro^[@CR34],[@CR36],[@CR38]^.

The sialoside binding site is required for S-mediated viral attachment and entry {#Sec4}
--------------------------------------------------------------------------------

To evaluate the importance of the interactions identified by cryo-EM for sialoside recognition, we substituted with alanine individual MERS-CoV S amino acid residues interacting with Neu5Ac and assessed the effect on domain A-mediated hemagglutination of human erythrocytes. As previously described, the wild-type MERS-CoV S domain A fused to human immunoglobulin Fc only promoted hemagglutination of human erythrocytes when multimerized on lumazine synthase nanoparticles^[@CR34]^, indicative of enhancement of low-affinity interactions via avidity (Fig. [3a](#Fig3){ref-type="fig"} and Extended Data Fig. [5a](#Fig9){ref-type="fig"}). Complete inhibition of hemagglutination was observed, however, for each binding site mutant tested, that is, F39A, H91A, I132A, S133A and R307A (Fig. [3a](#Fig3){ref-type="fig"} and Extended Data Fig. [5a](#Fig9){ref-type="fig"}). These results validated the structural observations by demonstrating that recognition of Neu5Ac via these residues is necessary for MERS-CoV S-mediated attachment to sialosides.Fig. 3The ligand-binding site is required for MERS-CoV S-mediated attachment to sialosides and entry into human airway epithelial cells.**a**, Hemagglutination assay using MERS-CoV S wild type (WT) or mutants. Wells positive for hemagglutination (HA) are encircled. F39A, H91A, I132A, S133A or R307A substitutions completely abrogated domain A-Fc-mediated hemagglutination of human erythrocytes. Mock-treated erythrocytes, absence of the protein A-fused lumazine synthase (pA-LS) or replacement of domain A with domain B (Dom. B) were used as negative controls. The assays were performed four times and a representative experiment is shown. **b**, MERS-CoV S F39A, H91A, S133A or R307A substitutions inhibited entry of pseudotyped murine leukemia viral particles into human airway Calu-3 cells. Data are normalized relative to wild type and shown as mean and s.d. of *n* = 3 pseudovirus experiments (technical replicates).

To further assess the functional relevance of the identified interactions, we interrogated the impact of individual domain A substitutions on MERS-CoV S-mediated entry into target cells. We used the murine leukemia virus platform with a luciferase reporter^[@CR43]^ for quantifying entry of particles pseudotyped with either wild-type or mutant MERS-CoV S into human airway Calu-3 cells. The S133A and R307A substitutions abrogated entry of pseudotyped particles due to disruption of the aforementioned electrostatic interactions involving the Neu5Ac C1 carboxylate and glycerol side chain, respectively (Fig. [3b](#Fig3){ref-type="fig"} and Extended Data Fig. [5b](#Fig9){ref-type="fig"}). The F39A and H91A mutants showed reduced infectivity of the pseudotyped particles by more than 90%, probably due to disruption of the ligand-binding groove and loss of favorable van der Waals or electrostatic interactions (Fig. [3b](#Fig3){ref-type="fig"} and Extended Data Fig. [5b](#Fig9){ref-type="fig"}). These findings demonstrate the key role of the identified residues for interacting with Neu5Ac in the context of a full-length, membrane-embedded MERS-CoV S glycoprotein and show that attachment to sialoside receptors using the binding site identified by cryo-EM is essential for promoting MERS-CoV S-mediated entry into human airway Calu-3 cells. Furthermore, as sialidase treatment of Calu-3 cells^[@CR34]^ or mutations of the S sialoside-recognition site abrogated MERS-CoV S-mediated entry, it is likely that sialoside attachment either precedes DPP4 engagement or occurs simultaneously.

MERS-CoV S specificity for α2,3-linked sialoside receptors {#Sec5}
----------------------------------------------------------

We previously showed that the MERS-CoV S domain A preferentially interacts with α2,3-linked, compared to α2,6-linked, sialosides, with sulfated sLeX being the preferred binder^[@CR34]^. To understand the architectural principles underlying this specificity, we determined three cryo-EM structures of MERS-CoV S 2P in the presence of 50 mM sLeX (Extended Data Figs. [1c](#Fig5){ref-type="fig"} and [6](#Fig10){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}), 70 mM 2,3-SLN (Extended Data Figs. [1d](#Fig5){ref-type="fig"} and [7](#Fig11){ref-type="fig"}, and Table [1](#Tab1){ref-type="table"}) or 70 mM 2,6-SLN (Extended Data Figs. [1e](#Fig5){ref-type="fig"} and [8](#Fig12){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}) at 2.7, 2.7 and 2.9 Å resolution, respectively.

The cryo-EM reconstruction obtained for MERS-CoV S in complex with sLeX resolves the terminal Neu5Ac linked to galactose, via a 2,3-glycosidic bond adopting a *cis* configuration, as well as the *N*-acetyl glucosamine (GlcNAc) and fucose rings at lower contour level due to conformational heterogeneity of the ligand (Fig. [4a,b](#Fig4){ref-type="fig"}). Engagement of the Neu5Ac moiety of the sLeX involves identical interactions to those observed in our structure of MERS-CoV S in complex with Neu5Ac (Fig. [1c--e](#Fig1){ref-type="fig"}). This finding, and the detection of a galactose moiety linked to the oxygen at position 2 of Neu5Ac, validate our docking of the ligand in the cryo-EM density. The sLeX trisaccharide core (Neu5Ac(α2--3)galactose(β1--4)GlcNAc) adopts a roughly linear conformation when bound to MERS-CoV S (Fig. [4a,b](#Fig4){ref-type="fig"}), as is the case for influenza virus hemagglutinins in complex with α2,3-sialosides^[@CR29],[@CR31],[@CR44]^. The MERS-CoV S structure in complex with 2,3-SLN shows a very similar pose of the ligand to that observed for sLeX, although the GlcNAc is even more conformationally heterogeneous in the trisaccharide compared to sLeX and was therefore not modeled (Fig. [4c,d](#Fig4){ref-type="fig"}).Fig. 4Structural basis of MERS-CoV S selectivity for α2,3-linked sialoside receptors.**a--f**, Enlarged views of the MERS-CoV S structures in complex with sLeX (**a**,**b**), 2,3-SLN (**c**,**d**) and 2,6-SLN (**e**,**f**). The cryo-EM densities corresponding to the ligands are shown as a blue mesh contoured at 3.7*σ* (**a**), 3.2*σ* (**b**), 5.8*σ* (**c**,**d**) and 4.5*σ* (**e**,**f**). **g**,**h**, The ligand-binding site with the sLeX and 2,6-SLN-bound MERS-CoV S structures superimposed, showing the distinct orientation of the two ligands relative to domain A. The asterisks indicate the proximity of the sLeX GlcNAc to the binding site, whereas the 2,6-SLN GlcNAc points away towards the solvent. In **a**--**d**, the A domain is rendered as a ribbon diagram with selected side chains of residues surrounding the sialoside shown as sticks. The ligands are rendered as sticks with atoms colored by elements (carbon, cyan (sLeX), green (2,3-SLN) or orange (2,6-SLN); nitrogen, blue; oxygen, red). Neu5Ac, 5-*N*-acetyl neuraminic acid; GlcNAc, *N*-acetyl glucosamine; Fuc, fucose; Gal, galactose.

The cryo-EM map obtained for MERS-CoV S bound to 2,6-SLN resolves the Neu5Ac and galactose moieties, linked via a 2,6-glycosidic bond adopting a *cis* configuration, and the GlcNAc ring at lower contour level due to conformational variability of the ligand (Fig. [4e,f](#Fig4){ref-type="fig"}). The 2,6-SLN has a U-shaped conformation, comparable to reports on influenza virus hemagglutinins^[@CR29],[@CR30]^, that positions the GlcNAc moiety away from the binding groove and the rest of the S glycoprotein (Fig. [4e,f](#Fig4){ref-type="fig"}).

The cryo-EM structures suggest an explanation for the finding that sulfated sLeX is the preferred MERS-CoV S sialoside ligand^[@CR34]^. Although the sLeX conformational dynamic limited its resolvability, the galactose and the GlcNAc moieties appear to be positioned within contact distance of the MERS-CoV S domain A due to the ligand conformation (Fig. [4a--d,g,h](#Fig4){ref-type="fig"}). Furthermore, sulfation of the GlcNAc hydroxyl group at position 6 could putatively allow formation of electrostatic interactions with the Gln304 side chain or neighboring residues (Fig. [4g,h](#Fig4){ref-type="fig"}), as described for influenza virus A/Vietnam/1194/2004 hemagglutinin^[@CR44]^. The bent architecture of 2,6-SLN, however, orients the GlcNAc away from the binding site, hindering contacts with S (which appear limited to the Neu5Ac and galactose moieties). We therefore hypothesize that the trend of preferential attachment to α2,3- over α2,6-sialosides results from enhanced interactions with the former type of ligand, leading MERS-CoV to target cell types presenting such sialylated receptors at their surface.

Discussion {#Sec6}
==========

We show here that sialosides bind to MERS-CoV S using a site distinct from the one observed for HCoV-OC43 S in complex with 9-*O*-acetyl sialylated receptors^[@CR19],[@CR39]^, despite the fact that the bound ligands are only separated by a few ångstroms from each other when superimposing the two structures. Although the β-sandwich architecture of domain A is conserved among all coronaviruses, distinct variable loops are grafted onto it, and neither the MERS-CoV S nor the HCoV-OC43 S sialoside-binding site is conserved in the infectious bronchitis virus S glycoprotein^[@CR10]^, which is known to engage α2,3-sialosides at the surface of avian host cells^[@CR45]^. These findings suggest coronavirus S glycoproteins have independently evolved the ability to recognize sialosides using domain A, similar to their ability to engage different proteinaceous receptors via modifications of domain B. Our results therefore set coronavirus S glycoproteins apart from influenza virus A hemagglutinins, which recognize the Neu5Ac moiety through a largely conserved binding site^[@CR29],[@CR30]^. We hypothesize that coronaviruses that utilize both an entry receptor and an attachment receptor for infection, such as MERS-CoV or transmissible gastroenteritis virus, have more evolutionary freedom with respect to their ability to attach to sialoglycans than viruses only using an entry receptor. This could have led to the independent loss and/or acquisition of a sialoside-recognition function as an adaption to new hosts upon cross-species transmission of distinct viruses. The ability to interact with sialoglycoconjugates might be a recent MERS-CoV S acquisition, as neither HKU4 S~1~ nor HKU5 S~1~ could hemagglutinate human erythrocytes^[@CR34]^. This modular evolutionary plasticity underlies coronavirus cross-species transmission, switching of host cell types and viral fitness.

We previously suggested that MERS-CoV S interacts with sialoside receptors through lower-affinity interactions than influenza A/California/04/2009 hemagglutinin (containing the T200A and E227A substitutions), as multimerization with a lumazine synthase nanoparticle was required to detect binding of a dimeric MERS-CoV S domain A-Fc construct but not of a dimeric hemagglutinin ectodomain-Fc construct^[@CR34]^. Because influenza A virus utilizes neuraminidase to promote the release of progeny virions from host cells, off-target cells or decoys, the enhanced affinity for sialosides is balanced with a receptor-destroying enzyme. Similarly, HCoV-OC43 possesses a hemagglutinin esterase with receptor-destroying activity^[@CR46]^ to achieve the same function. Because MERS-CoV does not encode an equivalent enzyme, the binding dynamic of viral particles to sialoside receptors is entirely based on the energetics of these reversible interactions^[@CR34]^. The strong dependence on interactions with sialosides for MERS-CoV entry into human airway Calu-3 cells is therefore probably a result of the high concentration of sialylated receptors^[@CR34]^, favoring virus adsorption through avidity and potentially increasing the likelihood of binding to DPP4, leading to viral entry. Similar roles have been proposed for carcinoembryonic antigen-related cell adhesion molecule 5 (ref. ^[@CR47]^) and binding immunoglobulin protein^[@CR48]^.

Although MERS-CoV S is densely decorated with N-linked glycans, the sialoside-recognition site is unobstructed, a possible requirement for receptor engagement. This finding is in marked contrast with the conformational masking and/or glycan shielding of the domain B entry receptor-binding motifs observed for several coronavirus S glycoproteins, including MERS-CoV S^[@CR13],[@CR15],[@CR18],[@CR20],[@CR21]^. We recently identified an antibody-blocking domain A-mediated hemagglutination of erythrocytes with in vitro neutralizing activity of MERS-CoV S pseudovirions and partial in vivo prophylactic protection of mice challenged with a lethal dose of MERS-CoV^[@CR49]^. These findings, along with our mutagenesis data, indicate that the sialoside-binding groove identified here represents a key site of vulnerability to inhibitors of MERS-CoV infection that could be targeted for the future development of therapeutics.

Methods {#Sec7}
=======

Cell lines {#Sec8}
----------

HEK293F is a cell line adapted to grow in suspension (Life Technologies). HEK293T/17 cells (ATCC, catalog no. CRL-11268) and human hepatic Huh-7 cells (National Institutes of Biomedical Innovation, Health and Nutrition, catalog no. JCRB0403) are adherent cells. Cell lines were not authenticated or tested for mycoplasma contamination.

Protein expression and purification {#Sec9}
-----------------------------------

The MERS-CoV S 2P ectodomain was produced in 500 ml HEK293F cells grown in suspension using FreeStyle 293 expression medium (Life Technologies) at 37 °C in a humidified 8% (vol/vol) CO~2~ incubator rotating at 130 r.p.m. The cultures were transfected using 293fectin (ThermoFisher Scientific) with cells grown to a density of one million cells per ml and cultivated for three days. The supernatants were harvested and cells resuspended for another three days, yielding two harvests. Clarified supernatants were purified using a 5 ml Cobalt affinity column (Takara). Purified protein was concentrated and flash-frozen in Tris-saline (50 mM Tris, pH 8.0, 150 mM NaCl) before cryo-EM analysis.

Protein A-fused lumazine synthase nanoparticles (a self-assembling 60-meric lumazine synthase nanoparticle, N-terminally extended with the immunoglobulin Fc-binding domain of the *Staphylococcus aureus* protein A) and Fc-tagged domain A (residues 19--357) or Fc-tagged domain B (residues 358--588) of the MERS-CoV S protein (GB, YP_009047204.1) were expressed and purified as previously described^[@CR34]^. Purified proteins were analyzed on a 12% (wt/vol) SDS--PAGE gel under reducing conditions and stained with GelCodeBlue stain reagent (Thermo Scientific).

Cryo-electron microscopy sample preparation and data collection {#Sec10}
---------------------------------------------------------------

Incubation of 1 μM MERS-CoV S 2P stabilized ectodomain trimer with 100 mM Neu5Ac (Millipore 110138), 100 mM Neu5Gc (Miilipore 362000), 50 mM sLeX (Carbosynth OS04058), 70 mM 2,3-SLN (Carbosynth OS06484) or 70 mM 2,6-SLN (Carbosynth OS09313) was performed overnight at 4 °C. We used 100 mM Neu5Ac based on our previous work on HCoV-OC43 S^[@CR19]^ and work on influenza virus^[@CR30]^, whereas the lower concentrations used for larger ligands were determined empirically based on the contrast of cryo-EM micrographs. A 3 μl volume of 0.16 mg ml^−1^ MERS S-sialoglycan complex was loaded onto a freshly glow discharged (30 s at 20 mA) lacey carbon grid with a thin layer of evaporated continuous carbon before plunge freezing using a vitrobot MarkIV (ThermoFisher Scientific) using a blot force of −1 and 2.5 s blot time at 100% humidity and 25 °C. Data were acquired using an FEI Titan Krios transmission electron microscope operated at 300 kV and equipped with a Gatan K2 Summit direct detector and Gatan Quantum GIF energy filter, operated in zero-loss mode with a slit width of 20 eV. Automated data collection was carried out using Leginon^[@CR50]^ at a nominal magnification of ×130,000 and a pixel size of 0.525 Å. The dose rate was adjusted to 8 counts per pixel per second, and each video was acquired in super-resolution mode fractionated in 50 frames of 200 ms.

Cryo-electron microscopy data processing {#Sec11}
----------------------------------------

Video frame alignment, estimation of the microscope contrast-transfer function parameters, particle picking and extraction were carried out using Warp^[@CR51]^. Particle images were extracted with a box size of 800 binned to 400 yielding a pixel size of 1.05 Å. For each dataset, two rounds of reference-free two-dimensional (2D) classification were performed using Relion^[@CR52]^ to select well-defined particle images. Subsequently, two rounds of 3D classification with 50 iterations each (angular sampling of 7.5° for 25 iterations and 1.8° with local search for 25 iterations) were carried out using Relion without imposing symmetry to select closed trimers with the three B domains in the down conformation. 3D refinements imposing *C*3 symmetry were carried out using non-uniform refinement in cryoSPARC^[@CR53]^ using an initial model generated by converting a modified version of PDB [6NB3](https://www.rcsb.org/structure/6NB3) (ref. ^[@CR20]^) with all three B domains closed to a map low-pass filtered to 30 Å resolution. Particle images were subjected to the Bayesian polishing procedure implemented in Relion3.0 (ref. ^[@CR54]^) before performing another round of 3D refinement in Relion followed by per-particle defocus refinement and, again, 3D refinement in Relion. The particles were then subjected to 3D classification without refining angles and shifts using a soft mask delineating the ligand-binding site and with a tau value of 60. Final 3D refinements were carried out using non-uniform refinement in cryoSPARC. Local resolution estimation, filtering and sharpening were carried out using cryoSPARC. Reported resolutions are based on the gold-standard Fourier shell correlation (FSC) of 0.143 criterion and Fourier shell correlation curves were corrected for the effects of soft masking by high-resolution noise substitution^[@CR55]^.

Model building {#Sec12}
--------------

We used UCSF Chimera^[@CR56]^ to fit the MERS-CoV S atomic model (PDB [6NB3](https://www.rcsb.org/structure/6NB3)) into the cryo-EM map followed by subsequent manually rebuilding using Coot^[@CR57],[@CR58]^. N-linked glycans were hand-built into the density where visible, and then refined and relaxed using Rosetta^[@CR59]--[@CR64]^. Glycan refinement relied on a dedicated Rosetta protocol, which uses physically realistic geometries based on prior knowledge of saccharide chemical properties^[@CR62]^, and was aided by using both sharpened and unsharpened maps. The final models were analyzed using MolProbity^[@CR65]^, EMRinger^[@CR66]^, Privateer^[@CR67]^ and PISA^[@CR68]^. Figures were generated using UCSF ChimeraX^[@CR69]^.

Pseudovirus entry assay {#Sec13}
-----------------------

Murine leukemia virus pseudotyped with MERS-CoV S was prepared as previously described^[@CR43]^. HEK293T/17 cells were co-transfected with a full-length MERS-CoV S or MERS-CoV S mutant encoding plasmid, a murine leukemia virus Gag-Pol packaging construct and the murine leukemia virus transfer vector encoding a luciferase reporter using the Lipofectamine 2000 or 3000 transfection reagent (Life Technologies) according to the manufacturer's instructions. Cells were incubated for 5--12 h at 37 °C and 8% CO~2~ with transfection medium. Cells were then washed with DMEM twice and DMEM containing 10% (vol/vol) FBS was added for 72 h. The supernatants were then harvested and filtered through 0.45 μm membranes before concentration with a 30 kDa centrifugal concentrator membrane (Amicon).

Calu-3 cells grown in DMEM containing 10% (vol/vol) FBS and 1% (vol/vol) PenStrep were plated into 96-well plates following trypsinization at a density of \~3.2 × 10^4^ cells per ml and allowed to grow for 48 h at 37 °C with 8% (vol/vol) CO~2~. The cells were washed three times with DMEM before addition of 40 μl of MERS-CoV S or MERS-CoV S mutant pseudovirus for 2 h at 37 °C with 8% (vol/vol) CO~2~. Following the 2 h incubation, 40 μl of 20% (vol/vol) FBS and 2% (vol/vol) PenStrep was added to the wells and the plate was incubated for 72 h. ONE-Glo-EX was added in equivolume (\~75 μl to account for evaporation) and the luciferase counts were read on a Varioskan plate reader.

Western blotting {#Sec14}
----------------

SDS--PAGE (4×) loading buffer was added to all concentrated pseudovirus samples. The samples were run on a 4--15% (wt/vol) gradient Tris-glycine gel (BioRad) and transferred to PVDF membranes. An anti-S~2~ MERS-CoV S purified 1.6c7 primary antibody^[@CR49]^ (1:500 dilution) and an Alexa Fluor 680-conjugated goat anti-human secondary antibody (1:40,000 dilution, Jackson Laboratory) were used for western blotting. A LI-COR processor was used to develop images.

Hemagglutination assay {#Sec15}
----------------------

High-sensitivity nanoparticle-based hemagglutination assays were performed as previously described^[@CR34]^. Briefly, wild-type or mutant MERS-CoV S domain A-Fc (starting at 6.77 μg per well) was complexed with protein A-fused lumazine synthase nanoparticles at a 0.6:1 molar ratio for 30 min on ice. Mixtures were subsequently serially diluted (twofold dilutions) and mixed 1:1 with human erythrocytes (0.5% (wt/vol) in phosphate buffered saline) in V-bottomed, 96-well plates. Hemagglutination was scored after 2 h of incubation at 4 °C.

Reporting Summary {#Sec16}
-----------------

Further information on research design is available in the [Nature Research Reporting Summary](#MOESM1){ref-type="media"} linked to this article.
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==============

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at 10.1038/s41594-019-0334-7.

Supplementary information
=========================

Reporting Summary

Extended data {#Sec18}
=============

Extended Data Fig. 1Chemical structures of the sialosides used for structural studies.**a**, Neu5Ac. **b**, Neu5Gc. **c**, sLeX. **d**, 2,3-SLN. **e**, 2,6-SLN.

Extended Data Fig. 2CryoEM analysis of the MERS-CoV S glycoprotein in complex with Neu5Ac at 2.7 Å resolution.**a,b**, Representative electron micrograph (**a**) and class averages (**b**) for the Neu5Ac-bound MERS-CoV S structure. **c**, Gold-standard (blue) and map/model (red) Fourier shell correlation curves. The 0.143 and 0.5 cutoffs are indicated by horizontal dashed lines. **d**, Local resolution map calculated using cryoSPARC. The Neu5Ac ligand is estimated to be resolved at 3Å resolution. **e**--**g**, Representative cryoEM densities shown as blue mesh with the corresponding atomic model rendered as sticks colored grey, blue and red for carbon, nitrogen and oxygen atoms, respectively. Dashed bonds indicate hydrogen bonds with ordered water molecules.

Extended Data Fig. 3Structural basis for the MERS-CoV S selectivity for neuraminic acids that are not 9-O-acetylated or 5-N-glycolylated.**a**, Superimposition of the 5-N-acetyl,9-*O*-acetyl neuraminic acid α-methyl glycoside (9-O-Ac-Neu5Ac, green) from the HCoV-OC43 S holo structure (PDB 6NZK^[@CR19]^) to the bound Neu5Ac from the MERS-CoV S/Neu5Ac complex structure suggests the MERS-CoV S sialoside-binding site could not sterically accommodate the 9-O-acetyl group in this conformation. The distances between the 9-O-acetyl group and His91 or Ala92 are indicated. **b**, The MERS-CoV S sialoside-binding site rendered as a ribbon diagram with the side chains of key surrounding residues shown. Neu5Ac is rendered with the corresponding region of cryoEM density from the MERS-CoV S/Neu5Ac complex structure (low-pass filtered to 3Å and scaled to the MERS-CoV S/Neu5Gc map) shown as a blue mesh contoured at 6σ. **c**--**f**, The cryoEM structure of MERS-CoV S in complex with Neu5Gc shows weaker density for the sialoside (blue mesh contoured at 6σ), indicating poor steric and/or chemical accommodation of the 5-N-glycolyl hydroxyl group in the hydrophobic pocket defined by Phe39, Phe101, Ile131 and Ile132. In panels (**c-e**) Neu5Gc was modeled based on the porcine rotavirus CRW-8 VP8\* holo structure (PDB 3TAY^[@CR41]^) which corresponds to the conformation observed in 1 out of 8 structures available in the protein data bank with a Neu5Gc analogue. In panel **f**, Neu5Gc was modeled based on the rhesus rotavirus VP8\* holo structure (PDB 3TB0^[@CR41]^) which is the only structure in the protein data bank featuring Neu5Gc with the 5-N-glycolyl group in an alternate orientation. The distance between the 5-N-glycolyl hydroxyl group and Gln36 is indicated.

Extended Data Fig. 4CryoEM analysis of the MERS-CoV S glycoprotein in complex with Neu5Gc at 3.0 Å resolution.**a**,**b**, Representative electron micrograph (**a**) and class averages (**b**) for the Neu5Gc-bound MERS-CoV S structure. **c**, Gold-standard Fourier shell correlation curve. The 0.143 cut-off is indicated by horizontal dashed lines. **d**, Representative density shown as blue mesh with the corresponding atomic model rendered as sticks colored grey, blue and red for carbon, nitrogen and oxygen atoms, respectively.

Extended Data Fig. 5SDS-PAGE and Western blot analyses.**a**, SDS-PAGE analysis of purified wild type or mutants MERS-CoV S domain A fused to human immunoglobulin Fc. Two micrograms of each protein was loaded. **b**, Western-blot analysis of murine leukemia viral particles pseudotyped with wild type or mutants MERS-CoV S using an anti-MERS-CoV S~1~ polyclonal antibody. Uncropped blot image is available as source data.[Source data](#MOESM2){ref-type="media"}

Extended Data Fig. 6CryoEM analysis of the MERS-CoV S glycoprotein in complex with sLeX at 2.7 Å resolution.**a**,**b**, Representative electron micrograph (**a**) and class averages (**b**) for the sLeX-bound MERS-CoV S structure. **c**, Gold-standard (blue) and map/model (red) Fourier shell correlation curves. The 0.143 and 0.5 cutoffs are indicated by horizontal dashed lines. **d**, Representative density shown as blue mesh with the corresponding atomic model rendered as sticks colored grey, blue and red for carbon, nitrogen and oxygen atoms, respectively.

Extended Data Fig. 7CryoEM analysis of the MERS-CoV S glycoprotein in complex with 2,3-SLN at 2.7 Å resolution.**a**,**b**, Representative electron micrograph (**a**) and class averages (**b**) for the 2,3-SLN-bound MERS-CoV S structure. **c**, Gold-standard (blue) and map/model (red) Fourier shell correlation curves. The 0.143 and 0.5 cutoffs are indicated by horizontal dashed lines. **d**, Representative density shown as blue mesh with the corresponding atomic model rendered as sticks colored grey, blue and red for carbon, nitrogen and oxygen atoms, respectively.

Extended Data Fig. 8CryoEM analysis of the MERS-CoV S glycoprotein in complex with 2,6-SLN at 2.9 Å resolution.**a**,**b**, Representative electron micrograph (**a**) and class averages (**b**) for the 2,6-SLN-bound MERS-CoV S structure. **c**, Gold-standard (blue) and map/model (red) Fourier shell correlation curves. The 0.143 and 0.5 cutoffs are indicated by horizontal dashed lines. **d**, Representative density shown as blue mesh with the corresponding atomic model rendered as sticks colored grey, blue and red for carbon, nitrogen and oxygen atoms, respectively.

Source data {#Sec20}
===========

Source Data Extended Data Fig. 5
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